TY - JOUR
T1 - Pioneering global best practices in atopic dermatitis
T2 - results from the atopic dermatitis quality of care initiative
AU - Guttman-Yassky, E.
AU - Nosbaum, A.
AU - Simpson, E.
AU - Weidinger, S.
N1 - Funding Information:
The GSG was comprised of the following: Professor E. Simpson (Portland, USA); Professor A. Nosbaum (Lyon, France); Professor Stephan Weidinger (Kiel, Germany); and Professor E. Guttman (New York, USA). We thank the following for their contributions insights and discussion: Dr W. Abramovits, Dr M. Alajlan, Professor M.V. Angles, Professor V. Aoki, Professor L. Bonzano, Professor M. de Bruin‐Weller, Professor C. Charman, Professor M. Deleuran, Dr L. Eichenfield, Dr A. Gonzalez, Dr P. Herranz, Professor M. Hide, Dr K. Igawa, Professor Y. Ihsiuji, Professor C. Jack, Dr Melissa Knuckles, Professor Y. Leshem, Dr P. Lio, Professor L. Misery, Professor K. Peris, Professor V. Piguet, Dr E. Serra‐Baldrich, Professor M.L. Schuttelaar, Professor D. Simon, Dr Med. R. von Kiedrowski, Professor B. Walker and Professor C.H. Yang. We also thank the staff at each of the centres that contributed their time, knowledge and experience who provided the foundation of the Initiative’s analyses and conclusions. We appreciate the efforts of KPMG LLP (UK) in executing the research, the editorial support provided by RxMedical Dynamics, LLC, New York, and the funding support of Sanofi Genzyme and Regeneron. This work was commissioned and funded by Sanofi Genzyme and Regeneron; the funders had no role in the collection, management, analysis or interpretation of data, or preparation of the final report.
Publisher Copyright:
© 2021 British Association of Dermatologists.
PY - 2022/2
Y1 - 2022/2
N2 - Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by unrelenting pruritus and recurrent eczematous lesions. It affects up to 15% of children and adolescents and up to 5% of adults, and confers a high and multifactorial burden to patients, families and society. With increasing awareness of this substantial burden, AD has become a priority for healthcare systems. Aim: The Atopic Dermatitis Quality of Care (ADQoC) initiative set out to describe good practices for addressing the challenges that impede the management of AD. Methods: The initiative carried out a literature review and surveyed 32 expert care centres, catalogued findings, and analysed and elucidated global challenges to AD care along with good practice implementations that can address them. Results: The four challenges to quality care for AD are: (i) misconceptions about AD; (ii) delayed referral and access to AD specialists; (iii) poor patient access to AD treatments and poor adherence to medications; and (iv) managing the complexity of AD and its comorbidities. The initiative highlighted 5 of 10 good practice implementations as high priority for any AD care centre to focus on: (i) clinical assessment and diagnosis; (ii) a structured multidisciplinary care team; (iii) monitoring and evaluating care quality; (iv) patient education and communication; and (v) collaboration and exchange with patient groups. Conclusion: These implementations can provide benefits for patients, healthcare providers and the healthcare system. They directly contribute to the efficacy of treatment, improved healthcare provider efficiency, improved education for patients and healthcare providers, and improved costs to healthcare systems. The initiative was launched on https://atopicdermatitiscare.kpmg.co.uk/ to provide an easy-to-use educational platform.
AB - Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by unrelenting pruritus and recurrent eczematous lesions. It affects up to 15% of children and adolescents and up to 5% of adults, and confers a high and multifactorial burden to patients, families and society. With increasing awareness of this substantial burden, AD has become a priority for healthcare systems. Aim: The Atopic Dermatitis Quality of Care (ADQoC) initiative set out to describe good practices for addressing the challenges that impede the management of AD. Methods: The initiative carried out a literature review and surveyed 32 expert care centres, catalogued findings, and analysed and elucidated global challenges to AD care along with good practice implementations that can address them. Results: The four challenges to quality care for AD are: (i) misconceptions about AD; (ii) delayed referral and access to AD specialists; (iii) poor patient access to AD treatments and poor adherence to medications; and (iv) managing the complexity of AD and its comorbidities. The initiative highlighted 5 of 10 good practice implementations as high priority for any AD care centre to focus on: (i) clinical assessment and diagnosis; (ii) a structured multidisciplinary care team; (iii) monitoring and evaluating care quality; (iv) patient education and communication; and (v) collaboration and exchange with patient groups. Conclusion: These implementations can provide benefits for patients, healthcare providers and the healthcare system. They directly contribute to the efficacy of treatment, improved healthcare provider efficiency, improved education for patients and healthcare providers, and improved costs to healthcare systems. The initiative was launched on https://atopicdermatitiscare.kpmg.co.uk/ to provide an easy-to-use educational platform.
UR - http://www.scopus.com/inward/record.url?scp=85115801127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115801127&partnerID=8YFLogxK
U2 - 10.1111/ced.14880
DO - 10.1111/ced.14880
M3 - Article
C2 - 34382243
AN - SCOPUS:85115801127
SN - 0307-6938
VL - 47
SP - 303
EP - 311
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 2
ER -